Core Viewpoint - Algenesis Labs has launched the world's first 100% plant-based isocyanate, Bio-Iso™, marking a revolutionary breakthrough in the polyurethane chemistry field, which aligns with global sustainability goals and meets increasing environmental regulations and consumer demand for safe, eco-friendly materials [2][4]. Production and Capacity Expansion - Algenesis Labs has commenced production at its pilot plant for Bio-Iso™ and is focused on expanding its production capacity in San Diego, California, while seeking strategic partners for global industrialization [4]. - The company has released a technical data package detailing the performance of Soleic® TPU materials made with Bio-Iso™ [4]. Environmental Impact - The introduction of Bio-Iso™ aims to break the cycle of environmental pollution and hazardous processes associated with traditional petroleum-based isocyanates, as it eliminates fossil carbon and phosgene from the supply chain [4][5]. Product Development - Algenesis Labs has developed bio-based polyols, bio-based polyurethane foams, and bio-based thermoplastic polyurethanes (TPU) from algae and non-food plants, marketed under the B2B brand Soleic® [5]. - The new Bio-Iso™ combined with bio-based polyols can produce 100% bio-based TPU, with several products already certified by the USDA as bio-based [6][10]. Product Certification and Applications - The Soleic® TPU products have varying levels of bio-based content, with TPU 1295A at 59%, TPU 1270A at 76%, TPU 1260D at 56%, and polyol LV-02 at 100% [6][10]. - Soleic™ bio-based polyols are utilized in soft polyurethane foam applications, initially used in flip-flops and later in Blueview shoes [7]. Strategic Partnerships - Algenesis is expanding its Soleic™ product line into breathable waterproof textiles and injection-molded products, having signed a collaboration agreement with Trelleborg for TPU coating on fabrics and partnered with RhinoShield for phone case production [9].

天眼查App显示，近日，常州峻安生物科技有限公司成立，法定代表人为陈圣平，注册资本100万人民 币，经营范围为许可项目：食品添加剂生产；饲料添加剂生产；食品生产；食品销售；化妆品生产（依 法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以审批结果为准）一般项目： 生物化工产品技术研发；食品添加剂销售；饲料添加剂销售；化工产品销售（不含许可类化工产品）； 技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；工业酶制剂研发；人工智能基础软 件开发；人工智能应用软件开发；货物进出口；技术进出口；细胞技术研发和应用；信息系统集成服 务；软件开发；发酵过程优化技术研发；化妆品批发（除依法须经批准的项目外，凭营业执照依法自主 开展经营活动）。 ...

浙江钱江生物化学股份有限公司 对外担保管理制度 （2025年8月5日经公司十届董事会2025年第五次临时会议审议通过） 为进一步加强公司对外担保管理，规范公司担保行为，控制公司经营风险， 按照《公司法》、《证券法》、《民法典》、《公司章程》及中国证监会《上市 公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》和《上海 证券交易所股票上市规则》（以下简称"《上市规则》"）及有关法律法规的规 定，特制定本制度。本制度所称对外担保，是指公司以第三人身份为他人提供保 证、抵押、质押或其他形式的担保，包括公司对控股子公司的担保。 本制度适用于公司及公司的全资子公司、控股子公司（以下合称"子公司"）。 第一条 董事会全体董事应当审慎对待和严格控制对外担保产生的债务风险， 对违规或失当的对外担保产生的损失依法承担连带责任。 第二条 公司对外担保应当遵守以下规定： （一）担保决策程序 公司股东大会和董事会是决策机构，公司的一切对外担保行为，必须按程序 经股东大会或董事会批准。下述担保事项应当在董事会审议通过后提交股东大会 审议： (1)本公司及本公司控股子公司的对外担保总额,超过最近一期经审计净资 产的50%以 ...

Core Viewpoint - Jiangsu Lanfeng Biological Chemical Co., Ltd. is currently involved in a legal dispute regarding securities false statements, with a total claim amount of RMB 19.18 million from 163 investors [2][3][4]. Group 1: Lawsuit Basic Information - The company has previously disclosed information regarding the investor lawsuit related to securities false statements [3]. - The final judgment and civil rulings from the Nanjing Intermediate People's Court have been received concerning the claims from 45 investors [3]. Group 2: Lawsuit Progress - The Nanjing Intermediate People's Court has issued an execution ruling to freeze RMB 19.18 million of the company's bank deposits due to non-compliance with a prior civil judgment [4]. - A total of 8 bank accounts of the company have been frozen, with only RMB 77,400 actually frozen [4]. - The company's overall business operations remain normal and unaffected by the bank account freeze [4]. Group 3: Company Response - The company plans to raise funds to comply with the court ruling and compensate the investors, aiming to lift the freezing measures promptly [5]. - The company will pursue accountability against its former directors and senior management as per the administrative penalty decision issued by the China Securities Regulatory Commission [5]. Group 4: Financial Impact - The total amount related to the investor lawsuit and associated costs is approximately RMB 19.18 million, which will be accounted for as liabilities and losses according to accounting standards [7]. - The company will continue to monitor the lawsuit's progress and fulfill its information disclosure obligations [7].

Group 1 - FDCA is a high-value bio-based compound with a wide range of applications, serving as a substitute for terephthalic acid and enabling the production of high-performance bio-based polymers [2][8] - The synthesis routes for FDCA are diverse, with the HMF route being the most promising and showing significant progress towards industrial production [17][18] - The global FDCA market is expected to grow at a compound annual growth rate (CAGR) of 8.9% from 2021 to 2028, potentially reaching $873.28 million by 2028 [4][51] Group 2 - Internationally, several companies have achieved FDCA production, with significant investments made since 2004, including major players like Coca-Cola, DuPont, and Avantium [3][35] - Domestic research on FDCA began around 2010 and has rapidly advanced, with notable breakthroughs in synthesis and polymerization processes [3][41] - The domestic industry is still in its early stages of commercialization, but there is a growing number of patents and publications, indicating a strong research foundation [3][41] Group 3 - PEF, derived from FDCA and ethylene glycol, exhibits superior properties compared to PET, including higher mechanical strength and better gas barrier performance, making it a promising alternative [5][10] - The application areas for PEF include food packaging, films, and fibers, with significant potential for replacing PET in various markets [5][10] - The production of PEF is expected to expand, driven by the increasing demand for sustainable materials and the growth of the bio-based product market [5][51] Group 4 - Companies like Avantium and Eastman are leading the way in FDCA production technology, with Avantium's YXY technology being a notable example [36][39] - Domestic companies such as Hefei Lif Biological and Zhongke Guosheng are making strides in FDCA production, with innovative processes and significant production capacity planned for the near future [44][45] - The collaboration between research institutions and companies is fostering innovation and accelerating the commercialization of FDCA and its derivatives in China [41][44]

Core Viewpoint - The article discusses the sustainable production of 1,4-butanediol (BDO) through engineered Escherichia coli, highlighting the potential for antibiotic-free fermentation methods and the optimization of metabolic pathways to enhance yield and efficiency [2][4][20]. Summary by Sections Introduction - 1,4-butanediol (BDO) is a significant non-natural chemical widely used in biodegradable plastics, with a substantial market potential. Traditional production relies on petrochemical methods, while biotechnological approaches face challenges such as low enzyme activity and high production costs [2][4]. Research Content - The study systematically optimized the E. coli chassis by integrating multiple copies of BDO synthesis genes, knocking out byproduct pathways, and engineering key enzymes to enhance metabolic flux. The introduction of a microaerobic fermentation strategy allowed for high BDO yields without antibiotics or inducers [4][5]. Metabolic Engineering Strategies - The research involved various strategies to improve BDO production, including: - Introducing external enzymes and optimizing gene expression to enhance BDO synthesis [7][11]. - Modifying the TCA cycle and enhancing ATP levels to redirect carbon flux towards BDO production [15][18]. - Utilizing the hok/sok system to maintain plasmid stability, achieving a low plasmid loss rate of 5.5% [18][19]. Production Results - In shake flask experiments, BDO production reached 7.88 g/L, the highest reported yield under similar conditions. In a 5-liter bioreactor, BDO production achieved 34.63 g/L with a glucose yield of 0.35 g/g and a production rate of 0.48 g/L/h [20][21]. Conclusion - The study demonstrates a comprehensive metabolic engineering approach for the sustainable industrial production of BDO from glucose, showcasing the potential for antibiotic-free processes and the need for further optimization to address byproduct accumulation [20][22].

一、监事会会议召开情况 江苏蓝丰生物化工股份有限公司（以下简称"公司"）第七届监事会第十九 次会议于 2025 年 7 月 28 日以通讯方式召开。本次会议通知已于 2025 年 7 月 25 日以微信、电子邮件的方式通知全体监事。本次会议由公司监事会主席韩宜辰先 生主持，应出席监事 3 人，实际出席监事 3 人。本次会议的召集、召开及表决程 序符合《公司法》和《公司章程》的规定，合法有效。 二、监事会会议审议情况 （一）审议通过《关于调整 2024 年限制性股票激励计划公司层面业绩考核 指标的议案》 证券代码：002513 证券简称：蓝丰生化 公告编号：2025-030 江苏蓝丰生物化工股份有限公司 本公司及监事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 经审核，监事会认为：公司对本激励计划中 2025 年和 2026 年公司层面业绩 考核指标的调整是基于公司目前行业发展状况和实际生产经营情况所做出的综 合考虑，目的是为更好地保障本激励计划的顺利实施，充分激发员工的内在动力 和潜能，符合《上市公司股权激励管理办法》等法律法规及本激励计划的相关规 定，调整程序合法、合规 ...

年7月28日召开，以8票赞同、0票反对、0票弃权，审议通过了《关于召开2025 年第一次临时股东会的议案》。 证券代码：002513 证券简称：蓝丰生化 公告编号：2025-033 江苏蓝丰生物化工股份有限公司 关于召开 2025 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 "公司"）2025年第一次临时股东会。 司股东会规则》和《公司章程》等有关规定。 （1）现场会议时间：2025年8月15日（周五）下午14:30。 （2）网络投票时间：2025年8月15日，其中： ①通过深圳证券交易所交易系统进行网络投票的具体时间为2025年8月15日 ②通过深圳证券交易所互联网投票系统进行网络投票的时间为：2025年8月 开。公司将通过深圳证券交易所交易系统和互联网投票系统向公司股东提供网络 形式的投票平台，公司股东可以在上述网络投票时间内通过深圳证券交易所的交 易系统或互联网投票系统行使表决权。股东只能选择现场表决和网络投票中一种 表决方式。 （1）在股权登记日持有公司股份的普通股股东或其代理人。 于股权登记日20 ...

证券代码：600165 股票简称：ST 宁科 公告编号：临 2025-086 宁夏中科生物科技股份有限公司 关于公司及子公司完成法人变更并换领营业执照的公告 类 型：股份有限公司（上市、自然人投资或控股） 法定代表人：符杰 注册资本：陆亿捌仟肆佰捌拾捌万叁仟柒佰柒拾伍圆整 成立日期：1998 年 05 月 14 日 住 所：宁夏石嘴山市惠农区河滨街 经营范围：许可项目：肥料生产（依法须经批准的项目，经相关部门批准后 方可开展经营活动）一般项目：生物基材料技术研发；生物基材料制造；生物基 材料销售；生物有机肥料研发；肥料销售；生物基材料聚合技术研发；生物化工 产品技术研发；新材料技术研发；工程塑料及合成树脂制造；合成材料制造（不 含危险化学品）；工程塑料及合成树脂销售；合成材料销售；工程和技术研究和 试验发展；新材料技术推广服务；技术服务、技术开发、技术咨询、技术交流、 技术转让、技术推广；技术进出口；化工产品销售（不含许可类化工产品）（除 许可业务外，可自主依法经营法律法规非禁止或限制的项目） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性 ...

Core Viewpoint - The article discusses the production and market potential of bio-based 1,4-butanediol (BDO), highlighting the shift towards sustainable chemical production methods in response to environmental concerns and regulatory pressures. Group 1: Bio-based BDO Production - Cargill and HELM AG's joint venture Qore has officially launched the production of bio-based BDO using locally grown dent corn, with a total investment of $300 million, aiming for an annual production capacity of 66,000 tons [3] - BDO is a crucial organic chemical and fine chemical raw material with extensive downstream applications across various industries, including textiles, pharmaceuticals, and biodegradable plastics [4] - The production of bio-based BDO is primarily achieved through fermentation processes, with Qore utilizing a proprietary one-step fermentation technology developed by Genomatica [8] Group 2: Industry Developments and Collaborations - LYCRA plans to use QIRA to enhance the sustainability of its fibers, potentially reducing its carbon footprint by up to 44% [5] - BASF has entered a long-term supply agreement with Qore to incorporate QIRA into its product portfolio, aiming for sustainable chemical production [5] - Several companies are investing in bio-based BDO production, including the Korean company Xinying Group, which plans to build a $1 billion facility in Vietnam, and Jinfa Technology, which has launched a 10,000-ton bio-based BDO project in Liaoning [9][10] Group 3: Market Trends and Future Outlook - The traditional BDO production methods face challenges due to high carbon emissions, necessitating the development of greener, low-carbon production processes [7] - Despite the current higher costs of bio-based BDO compared to petroleum-based BDO, its competitive advantage is expected to grow as oil prices remain high and production technologies improve [12] - The upcoming SynBioCon 2025 conference will focus on the development and industrial collaboration of key products that can replace petrochemical raw materials, indicating a strong industry shift towards sustainable practices [13]